Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

Contrast Enhanced Voiding Urosonography (ceVUS) With the Intravesical Administration of the Ultrasound Contrast Agent OPTISON TM (Trademark) for Vesicoureteral Reflux Detection and Urethral Imaging in Children.

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT02204917
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:37:04.708976+00:00
Published At
2018-11-27T00:00:00+00:00
Record Updated At
2018-11-27
Results Posted At
2018-11-27
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Vesico-Ureteral Reflux"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2018-11-27"
protocolSection.identificationModule.nctId
"NCT02204917"
protocolSection.identificationModule.officialTitle
"Contrast Enhanced Voiding Urosonography (ceVUS) With the Intravesical Administration of the Ultrasound Contrast Agent OPTISON TM (Trademark) for Vesicoureteral Reflux Detection and Urethral Imaging in Children."
protocolSection.statusModule.overallStatus
"COMPLETED"
protocolSection.designModule.phases
["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
"2018-11-27"

Study condition terms

  • Vesico-Ureteral Reflux (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.